Professional Media Briefs: Nature Publishing Group, Society for Investigative Dermatology, HMP Holdings, Reprints Desk and Elsevier

Share this article:
Nature Publishing Group (NPG) and the Society for Investigative Dermatology renewed their partnership to publish the Journal of Investigative Dermatology.

HMP Holdings, the parent company of journal publisher HMP Communications, named Jeff Hennessy CEO. Hennessy, who had been president and COO, replaces Paul Mackler. In 2007 Mackler and former HMP Holdings CFO Ken Fisher partnered with Alta Communications to acquire HMP Communications.

Derycz Scientific subsidiary Reprints Desk signed a content-distribution deal with UK-based publisher Informa, enabling Reprints Desk to sell individual articles in PDF and paper format from Informa's more than 1,000 peer-reviewed healthcare and life-science journals. Reprints Desk said it now has distribution deals with the world's five largest STM journal publishers.

With its first 2010 issue, Elsevier's Cell launched a new online format. Tabs link readers to the traditional sections of a research article, moving away from a linear format. Successful ideas from Elsevier's “Article of the Future” project are planned to be deployed across the company's portfolio of journals.
Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro